Effect of Personalized Elimination Diet on Food Sensitivity Related Symptoms

NCT ID: NCT05389683

Last Updated: 2024-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-02

Study Completion Date

2024-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal is to identify food sensitivity in patients and assess whether the avoidance of the reaction-inducing foods via an 'elimination diet' leads to improvement in patient symptoms and overall well-being.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After seeking appropriate consent, patients' blood samples will be tested for the reactivity toward 262 foods using peptide and protein microarrays. Food protein extraction will be carried out in different solvents such as water and alcohol. The peptide microarrays will synthesize the entire food proteins as peptides in situ while the protein microarrays will test for water-soluble and alcohol-soluble fractions. Thus, food sensitivity testing will be carried out at 3 different levels including water-soluble proteins, alcohol-soluble proteins, and peptides. Patients' blood samples can be tested at all 3 levels or a combination of these. This decision lies at the discretion of the physician.

Based on the test results and as per the physician's recommendations, a suitable elimination diet will be suggested to the patient. Personalized diet suggestions for each patient will be made by the physician. The patient will follow the diet for 4 weeks and blood samples will be tested again on completion of the diet, using peptides and protein microarrays. Additionally, based on the physician's recommendations, the time duration for which a patient follows the personalized elimination diet can be modified.

The patients will periodically have to fill out diagnostic questionnaires which will help assess the changes in their food sensitivity-related symptoms. Changes in the blood biomarkers and improvement in symptoms will be monitored during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Sensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

It is a single group study in which a single group of subjects will receive a single intervention and the outcomes will be assessed over time.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elimination Diet

Participants will be suggested an 'Elimination diet' that will be devoid of the reaction-inducing foods and it shall be followed for 4 weeks.

Group Type EXPERIMENTAL

Elimination Diet

Intervention Type BEHAVIORAL

An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elimination Diet

An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18 to 65 years.
* Patients suffering from food sensitivity symptoms
* Patients having Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-mediated food reactions leading to food sensitivity
* Patients agreeing to follow the diet per testing
* Patients willing to provide an informed consent

Exclusion Criteria

* Patients suffering from chronic medical conditions like cancer
* Pregnant subjects
* Patients who have recently used antibiotics
* Patients who have previously undergone treatments for food allergies/sensitivities
* Patients who have been assigned an elimination diet before
* Patients who are already following a restricted diet of any kind
* Patients unwilling/unable to provide informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vibrant America Clinical Lab

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hari Krishnamurthy

Director - Biomedical Engineering

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hari K Krishnamurthy, M.S.

Role: PRINCIPAL_INVESTIGATOR

PI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hope Natural Health

Gilbert, Arizona, United States

Site Status

Inside Out Aesthetics

Scottsdale, Arizona, United States

Site Status

Vitality MD's

Scottsdale, Arizona, United States

Site Status

Mr. Hari Krishnamurthy

San Carlos, California, United States

Site Status

Vitality Health and Wellness

Miami Beach, Florida, United States

Site Status

Institute for Hormonal Balance

Orlando, Florida, United States

Site Status

One Agora Integrative Health

Bloomington, Minnesota, United States

Site Status

Turnpaugh Health and Wellness Center - Manheim

Manheim, Pennsylvania, United States

Site Status

Turnpaugh Health and Wellness Center - Mechanicsburg

Mechanicsburg, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB # 1-1586736-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Allergy Experience Study
NCT03513965 COMPLETED NA
Gluten Sensitivity in Non-Celiac Patients
NCT01485341 COMPLETED PHASE3
Microbiota and Allergy
NCT04750980 COMPLETED